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Natural killer cells are controlled by peptide selective inhibitory receptors for MHC class
I, including the killer cell immunoglobulin-like receptors (KIRs). Despite having similar
ligands, KIR2DL2 and KIR2DL3 confer different levels of protection to infectious disease.
To investigate how changes in peptide repertoire may differentially affect NK cell reac-
tivity, NK cells from KIR2DL2 and KIR2DL3 homozygous donors were tested for activity
against different combinations of strong inhibitory (VAPWNSFAL), weak inhibitory (VAP-
WNSRAL), and antagonist peptide (VAPWNSDAL). KIR2DL3-positive NK cells were more
sensitive to changes in the peptide content of MHC class I than KIR2DL2-positive NK cells.
These differences were observed for the weakly inhibitory peptide VAPWNSRAL in single
peptide and double peptide experiments (p < 0.01 and p < 0.03, respectively). More sig-
nificant differences were observed in experiments using all three peptides (p < 0.0001).
Mathematical modeling of the experimental data demonstrated that VAPWNSRAL was
dominant over VAPWNSFAL in distinguishing KIR2DL3- from KIR2DL2-positive donors.
Donors with different KIR genotypes have different responses to changes in the peptide
bound by MHC class I. Differences in the response to the peptide content of MHC class I
may be one mechanism underlying the protective effects of different KIR genes against
infectious disease.
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Introduction
NK cells are innate lymphocytes involved in the immune response
to viruses and cancer, either through direct interaction with tar-
get cells or through interactions with macrophages, dendritic cells,
and T cells [1, 2]. They express activating and inhibitory receptors
on the cell surface and signals transduced from these receptors are
integrated to determine whether or not an individual NK cell is
activated [3]. While the activating receptors are derived from a
number of different gene families and have diverse ligands, the
dominant inhibitory receptors expressed on NK cells are either
from the killer cell immunoglobulin-like receptor (KIR) family or
the C-type lectin-like receptor CD94:NKG2A and have MHC class
I ligands [4, 5]. Thus NK cell responses can be fine-tuned by inter-
actions with many different ligands including MHC class I.
A number of immunogenetic studies have highlighted the con-
tribution that the KIR/MHC system makes to human disease
including viral infections, pregnancy-associated disorders, autoim-
mune disease, and cancer [6–8]. The HLA-C specific KIR are impli-
cated in the immune response to diseases such as HCV, HIV,
malaria, and psoriatic arthropathy [9–14]. For instance, in HCV
infection, KIR2DL3 in combination with its HLA-C group 1 ligands
is protective, whereas KIR2DL2, which also has group 1 HLA-C
allotypes as ligands, is not [15–17]. Binding studies have shown
that KIR2DL2 is a higher affinity receptor for group 1 HLA-C allo-
types than KIR2DL3, suggesting that KIR2DL3-positive NK cells
are more easily activated than their KIR2DL2-positive counter-
parts. However, in functional experiments, no difference has been
observed in the inhibition of KIR2DL2- and KIR2DL3-positive NK
cells by group 1 HLA-C alleles [18, 19]. Binding of both KIR2DL2
and KIR2DL3 to MHC class I is dependent on the peptide bound
by HLA-C [20–22]. However, this is a broad specificity defined by
residues 7 and 8 of the bound peptide as distinct from the fine
specificity of the T-cell receptor. Recent work has demonstrated
an unexpected sensitivity of NK cells to combinations of peptides
presented by MHC Class I [23, 24]. Thus, when the peptide VAP-
WNSDAL is presented by HLA-Cw*0102 it does not alter the reac-
tivity of KIR2DL2- and KIR2DL3-positive NK cells. However, it can
significantly reduce the inhibition due to a strong inhibitory pep-
tide VAPWNSFAL in a process termed “peptide antagonism.” This
implies that NK cells may be sensitive to changes in peptide reper-
toire and, based on the immunogenetic findings, suggests that
KIR2DL2- and KIR2DL3-positive NK cells may respond differently
to these changes.
We originally screened a panel of P7 and P8 variants of VAP-
WNSLSL, a naturally processed HLA-Cw*0102 epitope [23, 25].
We identified three classes of peptides, strong inhibitory peptides,
weak inhibitory peptides, and noninhibitory/antagonist peptides
[23]. We postulate that these represent the major classes of pep-
tides presented byMHC class I that can influence NK cell reactivity.
We have used peptides representative of these different categories
to investigate how NK cells from donors with different genetic
backgrounds (KIR2DL3 homozygotes and KIR2DL2 homozygotes)
may respond to changes in the peptide content of MHC class I.
Results
A weakly inhibitory peptide discriminates KIR2DL2-
poisitve NK cells from KIR2DL3-positive NK cells
We have used the 721.174 cell line to study the interaction of KIR
with group 1 HLA-C. This cell line expresses HLA-C*0102, but as
it is deficient in TAP, the HLA on the cell surface is expressed with
low affinity peptide, and can therefore be exogenously loaded
with peptide. Using this cell line for a peptide screen we iden-
tified VAPWNSFAL (VAP-FA) as a high affinity ligand for KIR,
VAPWNSDAL (VAP-DA) as a low affinity ligand and VAPWNSRAL
(VAP-RA) as having an intermediate affinity for both KIR2DL2
and KIR2DL3 (Fig. 1A–C) [23]. The peptides have similar affini-
ties for HLA-Cw*0102 the allele naturally expressed on 721.174
cells (Fig. 1A and Supporting Information Fig 1). This binding
correlates well with function in that VAP-FA is strongly inhibitory,
VAP-RA is weakly inhibitory and VAP-DA is noninhibitory for both
KIR2DL2 and KIR2DL3 homozygous donors (Fig. 1D–F). To inves-
tigate whether different donors had different responses to single
peptides, 721.174 cells were loadedwith VAP-FA, VAP-RA, or VAP-
DA and used as targets for CD158b+ NK cells from eight KIR2DL3
homozygous and six KIR2DL2 homozygous donors in degran-
ulation assays. VAP-FA and VAP-RA inhibited CD158b-positive
NK cells from both sets of donors at all peptide concentrations
(Fig. 2A–C). This is consistent with our previous data showing
that in a single peptide model, inhibition is determined by levels
of MHC class I expression, and this starts to decline significantly
only at levels of less than 2 μM peptide. However, there was a
difference in the level of inhibition between the two donor groups
for the weakly inhibitory VAP-RA peptide (p = 0.01). This was
more evident at higher levels of VAP-RA in which NK cells from
the KIR2DL2-positive donors were marginally more inhibited than
those from KIR2DL3-positive donors (8 μM VAP-RA [p < 0.001]
or 10 μM VAP-RA [0.1 > p > 0.05]) (Fig. 2B). Double peptide
experiments were conducted using a final peptide concentration
of 10 μM and varying the relative proportions of the two pep-
tides. Consistent with our previous data VAP-DA behaved as a
peptide antagonist in that it reduced inhibition due to VAP-FA,
despite not binding to KIR2DL2-Fc or KIR2DL3-Fc, or inhibiting
KIR2DL2- or KIR2DL3-positive NK cells. For instance, at 4 μM
VAP-FA alone CD107a expression was approximately 40% of max-
imum in the absence of VAP-DA (Fig. 2A), but in its presence
(VAP-DA 6 μM) CD107a expression was 80% (Fig. 2D). Overall
CD158b-positive NK cells from both KIR2DL2- and KIR2DL3-
positive donors were inhibited at similar levels for the VAP-
FA/VAP-DA and VAP-FA/VAP-RA ratios tested (Fig. 2D and E).
However, we observed small but significantly increased inhibition
of NK cells from the KIR2DL2-positive donors for VAP-RA/VAP-
DA mixtures overall (p < 0.03 (two-way ANOVA)) (Fig. 2F).
Thus, similar to the single peptide experiments significant differ-
ences between the donors were seen with the weak inhibitory
peptide VAP-RA, rather than the strongly inhibitory peptide
VAP-FA.
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Figure 1. Correlation of KIR binding with NK cell inhibition in KIR2DL2+ and KIR2DL3+ donors. (A) Stabilization of HLA-Cw*0102 on 721.174
by the indicated VAPWNSLSL derivative peptides and a control peptide (VMAPRTLFL) at saturating concentrations 10 μM (filled histograms).
The no primary Ab control is indicated in each plot and the titration of the peptides is shown in the far right panel. Binding of (B) KIR2DL2
or (C) KIR2DL3 fusion constructs to 721.174 cells in the presence (filled lines) or absence of the indicated peptide at a concentration of 10 μM.
Representative histograms (n = 3 samples) are shown. Summaries of the mean fluorescence intensities (MFI) of KIR-binding pooled from two
independent experiments are shown in the far right panels (**p < 0.01, ***p < 0.001; Student’s t-test). Gating strategy and degranulation assays of
CD158b-positive CD3-CD56+ NK cells from (D) KIR2DL2 homozygous or (E) KIR2DL3 homozygous donors in response to 721.174 cells incubated
with the indicated peptides at a final concentration of 10 μM. Representative histograms of six 2DL2 and eight 2DL3 donors, analyzed in duplicate,
are shown.
Differences between KIR2DL2- and KIR2DL3-positive
NK cells are greater at lower levels of inhibition
In order to explore the effects of changing class I-bound peptide
in more detail we devised experiments using peptides of all three
categories: strongly inhibitory, weakly inhibitory, and antagonis-
tic. These experiments were conducted using fixed ratios of
weak/strong inhibitory peptides (VAP-RA:VAP-FA) and then
gradually increasing the amount of antagonistic VAP-DA in the
mix (Supporting Information Table 1). All experiments were
performed at a final peptide concentration of 10 μM. Overall there
was a highly significant difference between the two groups of
donors as determined by two-way ANOVA (p < 0.0001) (Fig. 3).
For each ratio of VAP-RA:VAP-FA overall there were statistically
significant differences in the change in inhibition of CD158b-
positive NK cells induced by the addition of VAP-DA between
the KIR2DL2 and KIR2DL3 homozygotes (Fig. 3). However, the
patterns varied with VAP-RA:VAP-FA ratio. When the strongly
inhibitory peptide predominated (20%:80% VAP-RA:VAP-FA)
there were small, but individually insignificant differences
induced by the antagonist between the donor groups at all
VAP-RA:VAP-FA ratios (Fig. 3A). For 40%:60% and 60%:40%
VAP-RA:VAP-FA the differences were more evident at higher
concentrations of VAP-DA, and reached statistical significance at
6 μM VAP-DA (p < 0.05 and p < 0.01, respectively) (Fig. 3B and
C). When the weakly inhibitory peptide predominated (VAP-RA:
C© 2014 The Authors. European Journal of Immunology published by
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Figure 2. Comparison of inhibition of CD158b+ NK cells from KIR2DL2+ and KIR2DL3+ donors by individual peptides and double peptide com-
binations. 721.174 cells were incubated with the indicated peptides and used as target cells in degranulation assays for CD158b-positive NK
cells from eight KIR2DL3 homozygous donors and six KIR2DL2 homozygous donors. The individual responses of KIR2DL2 (circles) and KIR2DL3
(squares) donor NK cells to (A) VAP-FA, (B) VAP-RA, and (C) VAP-DA are shown. The dashed line connects the mean of the results from the KIR2DL2
homozygous donors and the full line the KIR2DL3 donors. (D–F) Responses to pairs of peptide are shown with the final concentration of peptides in
all mixes being 10 μM. The concentration of each of the peptides is indicated on each x-axis. Data show the mean value for each individual donor,
and are from one experiment performed in duplicate. p values for the differences between the donors as determined by ANOVA are indicated. For
comparisons at individual peptide concentration *0.05 < p < 0.1 and **p < 0.001. Degranulation data are normalized to 721.174 with no peptide.
VAP-FA, 80%:20%), differences induced by the antagonist were
more evident at low concentrations of VAP-DA and were signifi-
cant at both 2μMand 4μM (p < 0.001 and p < 0.01, respectively)
(Fig. 3D). Degranulation saturates at higher concentrations of
VAP-DA therefore differences are no longer apparent. Thus, in
general, differences between the donors were observed at lower
levels of inhibition. Analyzing the subgroup of donors with ligands
for KIR2DL2 and KIR2DL3 (group 1 HLA-C positive) gave similar
results to the overall cohort (Supporting Information Fig. 2).
Response to changes in peptide repertoires
discriminates KIR2DL2 from KIR2DL3-positive donors
In order to describe these data quantitatively, we constructed a
regression model. The model assumes that the degranulation (A),
quantified by CD107a in a population of NK cells, varies with
concentrations of FA, DA, and RA peptides as,
A = 100% − kF [FA] − kD [DA] − kR [RA]
+ kDF [DA] [FA] + kFR [FA] [RA]
+ kRD [RA] [DA] + kDFR [DA] [FA] [RA] . (1)
First we evaluated the parameters in the model in the absence
of any cubic order term, i.e. kDFR = 0. We also set kDA = 0 as DA
minimally affects activation when NK cells are stimulated with DA
Table 1. . Parameter values obtained by minimizing χ2
Parameter values KIR2DL2 donor KIR2DL3 donor
kF 6.4 6.05
kD 0 0
kR 5.27 2.36
kDF 0.003 0.0007
kFR 0.018 0.0016
kRD 0.125 0.54
kDFR 0 0
χ2 12.6 8
peptide alone. When searching for parameter values we restricted
the search to only positive values as the peptides have been shown
to induce inhibition in single peptide experiments (kF, kD, kR) and
antagonize inhibition in two and three peptide experiments (kDF,
kFR, kRD, kDFR). Themodel in Eq. (1) agreed slightly better with the
data from KIR2DL3 donors compared with the KIR2DL2 donors.
This is reflected in the larger values of χ2 (Table 1) produced for
the KIR2DL2 data.
From the parameter values in Table 1, the [FA]–[DA] and [FA]–
[RA] pairs appear to have less impact in inducing activation com-
pared with the [DA]–[RA] pair in the triple peptide experiments.
The qualitative features of the model did not change when we
added the cubic term in estimating the model parameters. Thus
the [RA]–[DA] pair seemed to exert more influence in activation
compared with the other two pairs.
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Figure 3. Comparison of inhibition of CD158b+ NK cells from KIR2DL2+ and KIR2DL3+ donors to different combinations of VAP-FA, VAP-DA, and
VAP-RA. (A–D) 721.174 cellswere incubatedwith combinations of three peptides as shown in Table 1 and used as target cells in degranulation assays
for CD158b-positive NK cells from KIR2DL2 (circles) and KIR2DL3 (squares) homozygous donors. The mean CD107a expression levels normalised
to no peptide are connected by a dashed line (KIR2DL2 homozygous donors) or a full line (KIR2DL3 homozygous donors). The ratios of VAP-RA
to VAP-FA were: (A) 20% VAP-RA:80% VAP-FA, (B) 40% VAP-RA:60% VAP-FA, (C) 60% VAP-RA:40% VAP-FA, and (D) 80% VAP-RA:20% VAP-FA. In all
experiments, the VAP-RA:VAP-FA ratio was kept constant but the total quantity was varied in combination with VAP-DA in order to maintain a
total peptide concentration of 10 μM in the peptide mix (Supporting Information Table 1). Data show the mean value for each individual donor,
and are from one experiment performed in duplicate. p values for the differences between the donors as determined by ANOVA are shown. For
comparisons at individual peptide concentrations *p < 0.05, **p < 0.01, ***p < 0.001.
The fitted function shows that KIR2DL3 expressing cells are
activated more easily than the KIR2DL2 expressing cells (Fig. 4A).
This is shown in Fig. 4B in which the peptide combinations that
produce more than 65% CD107a degranulation are shown in red.
This shows that activation stays below 65% (shown in green) for
a greater fraction of peptide combinations for KIR2DL2-positive
NK cells, compared with KIR2DL3-positive NK cells. Thus 12 out
of 25 peptide combinations for KIR2DL2 donors and 7 out of
25 peptide combinations for KIR2DL3 donors yielded a degranu-
lation value of less than 65%. The role of the [DA]-[RA] pair seems
to be greater for KIR2DL3 (KRD = 0.54) compared with KIR2DL2
(KRD = 0.125). This is also consistent with the single peptide data
in which KR for KIR2DL2 is approximately twice that for KIR2DL3.
Based on the data in Table 1 the differences in inhibition between
KIR2DL3 and KIR2DL2 donors can be given by:
Inhibition2DL2−2DL3 = −2.91 [RA] − 0.415 [RA] [DA]
− 0.35 [FA] − 0.004 [DA] [FA]
+ 0.00164 [FA] [RA] (2)
Therefore the [RA] term is dominant over the [FA] term and the
[RA][DA] term dominant over [FA][DA]. Thus these data imply
that KIR2DL3-positive NK cells respond more readily to changes in
peptide repertoire than KIR2DL2-positive NK cells, and the differ-
ence in inhibition between donors is determined by the concentra-
tions of the weak agonist peptide and the weak agonist/antagonist
peptide combination.
Discussion
We have used a model system to investigate how NK cells may
respond to changes in peptide repertoire. We have assumed that
there are four broad classes of peptide/MHC class I with respect
to KIR: strong inhibitory, weak inhibitory, antagonistic, and null,
with null peptides not contributing to NK cell signaling. We, there-
fore, modeled changes in peptide repertoire using representatives
of the three classes of peptide that could modulate changes in NK
cell activity. It has previously been shown that CD107a degranu-
lation correlates well with binding using KIR-Fc fusion constructs
and that the selected peptides are representative of these groups,
with VAP-FA being the strongest binder in our peptide screen,
VAP-DA being one of the nonbinders and VAP-RA being inter-
mediate between the two [23]. Our experimental and model-
ing data indicate that there are differences in the way that
C© 2014 The Authors. European Journal of Immunology published by
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Figure 4. Regressionmodeling of experimental data
fromassays of inhibition using the triplemix peptide
combinations. (A) Comparison between the model
and the experiments. The activation determined by
the model (gray surface) in Eq. (1) for the param-
eter values noted in Table 1 when the cubic term
in Eq. (1) was set to zero. The points show the
measured %CD107a degranulation averaged over
multiple trials (n  3). The left panel shows the
comparison for KIR2DL2-positive donors and the
right panel for KIR2DL3-positive donors. (B) Com-
parison of the regression models for KIR2DL2 and
KIR2DL3-positive donors. The peptide combinations
determined by Eq. (1) that produce greater than
65% degranulation as compared with no peptide
for KIR2DL2 donors (left panel) and KIR2DL3 donors
(right panel). Degranulation of more than 65% is
shown in red, and less than 65% is shown in green.
Computer generated graphics from data in Fig. 3 are
shown.
CD158b-positive NK cells from donors with different KIR geno-
types respond to changes in peptide repertoire.
It has been shown previously that KIR2DL2 has a greater
affinity for HLA class I than KIR2DL3 due to a difference in the
hinge angle between the two domains of the receptors [18, 19].
However, functional experiments did not detect differences in
inhibition by group 1 HLA-C alleles between KIR2DL2 and
KIR2DL3-positive NK cells. These experiments were performed
using transfectant cell lines expressing single HLA-C alleles, which
are strongly inhibitory, and this is consistent with our observa-
tions that VAP-FA is not discriminatory between the two donor
genotypes. Our data show that functional differences are more
subtle and related to the peptides presented by MHC class I. Thus,
in single peptide experiments both sets of donors made similar
responses to VAP-DA and VAP-FA, but not to VAP-RA. In the triple
mix experiments, the ratio of VAP-RA to VAP-DA appeared to be
the most discriminatory between the donors, but in the mathe-
matical analysis the concentration of VAP-RA appeared dominant
over the combination of the two.
The observed differences between the donors are small. How-
ever, given that KIR2DL2 and KIR2DL3 differ on average by only
4 amino acids in the D1 and D2 domains this is not surprising.
Additionally, large immunogenetic studies have been required
to define the protective effects of KIR against infection, arguing
against individual KIR having dramatic effects and demonstrating
the subtly of functional polymorphisms within the KIR system.
Our data show that in this model system changes in peptide
repertoire lead more readily to activation of KIR2DL3-positve NK
cells than KIR2DL2-positive NK cells. Testing of these data with
additional peptide/HLA combinations would assist in establish-
ing the broad applicability of these findings. Furthermore, the in
vivo significance of this work needs further exploration. How-
ever, changes in peptide repertoire may occur during viral infec-
tion or tumorigenesis through the presentation of viral antigens,
tumor antigens or self-peptides [26]. The formation of the MHC
class I peptide repertoire is complex and appears to depend on
a combination of the degradation of mature proteins, and also
recently synthesizedmisfolded proteins (defective ribosomal prod-
ucts “DRiPs”) [27, 28]. Viral infection can readily change the MHC
class I peptide repertoire either by presentation of viral peptides,
but also by changing the self-peptides presented by MHC class I.
Moreover, the induction of the immunoproteosome by proinflam-
matory signals during an active immune response is likely to signif-
icantly alter the peptide landscape presented by MHC when com-
pared with noninflammatory conditions. At an early time point
during vaccinia infection, nearly 50% of the peptide repertoire of
MHC class I is composed of viral peptides [29]. Therefore, changes
in peptide repertoire during viral infection can be substantial
and, based on our data, potentially sufficient to activate an NK
cell. Peptide antagonism is a mechanism that permits detection
of changes in peptide repertoire and this would be more read-
ily accomplished in the presence of weaker inhibitory peptides.
Based on our peptide-binding screen, the subset constituting the
inhibitory peptides form a continuum of which VAP-RA is at the
weaker KIR-binding and VAP-FA at the stronger KIR-binding ends.
Thus, although other peptides may have subtly different effects the
peptide combinations tested broadly represent changes in MHC
class I peptide repertoire.
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The modeling data provide a template for how the inhibition
of NK cells may change in response to the peptide content of
MHC class I and the better fit of the model in Eq. (1) with the
data for KIR2DL3 compared with KIR2DL2, could indicate the
presence of additional factors, that modulate NK cell function
for only KIR2DL2 donors. One such factor could be KIR2DS2,
which is also bound by the CD158b antibody used in this study.
KIR2DS2 is in strong linkage disequilibrium with KIR2DL2, there-
fore all our KIR2DL2 donors also had this activating receptor. It
has recently been shown that HLA-A11 is a ligand for KIR2DS2 and
that KIR2DS2-positive NK cell clones can recognize HLA-Cw*0304
[30, 31]. However, we were unable to confirm or refute a role for
KIR2DS2 as excluding these individuals meant that numbers were
too small for statistical analysis. However, the affinity of KIR2DS2
for HLA class I is much lower than for KIR2DL2 [22] and in our
experiments NK cells from the KIR2DL2 donors were inhibited
to a greater extent than those from the KIR2DL3 donors. Taken
together, this suggests that the effect of KIR2DS2 in these experi-
ments is likely to be small, if any.
KIR2DL3, but not KIR2DL2 has been shown to be protective
against viral infection such as hepatitis C virus and also against
fulminant malaria. It is thought that the selection for the KIR
A haplotype, containing KIR2DL3, is related to defense against
pathogens. Our data suggest that fine tuning of NK cell activity by
MHC class I peptide may discriminate KIR2DL3, from KIR2DL2,
positive donors in a manner that allows marginally greater reac-
tivity of KIR2DL3-positive NK cells. These subtle differences may
be important for understanding how KIR contribute to the genetic
susceptibility to infectious disease.
Materials and methods
Peptide stabilization assay
The HLA-Cw*0102-positive, TAP deficient 721.174 cell line was
cultured in RPMI medium 1640 supplemented with 1% peni-
cillin/streptomycin (Invitrogen, Paisley, UK) and 10% fetal calf
serum (Lonza). For peptide stabilization, 2 × 105 721.174 cells
were incubated with or without synthetic peptides (GL Biochem,
Shanghai Ltd., China) overnight at 26°C. After 16 h, cells were
washed and stained with a primary HLA-Cw*0102-specific anti-
body VP6G3 for 1 h at room temperature, followed by a secondary
FITC-conjugated goat anti-human IgM antibody (AbD Serotec) for
30 min at room temperature. Cells were then washed and fixed in
1% PFA/ fetal calf serum. Cells were analyzed by flow cytometry
(BD Biosciences, Oxford, UK). The mean intensity of fluorescence
of 10 000 events was collected.
KIR2DL2/3-Fc binding assay
KIR2D2L2-IgG and KIR2DL3-IgG fusion constructs (KIR2DL2-Fc &
KIR2DL3-Fc Chimera; R&D Systems) were conjugated with pro-
tein A Alexa Fluor 488 (Invitrogen) at a molar ratio of 6:1. A total
of 1 × 106 721.174 cells were incubated with 10 μM peptide as
described above and then stained with KIR-Fc. After fixation in
4% w/v paraformaldehyde cells were analyzed by flow cytometry.
CD107a NK cell degranulation assay
Human PBMC were isolated from the blood of 14 healthy donors
using Hypaque-Ficoll (GE Healthcare, Amersham, UK) density
centrifugation, with informed consent and full ethical approval
(REC ref 06/Q1701/120). A total of 3 × 105 PBMCs were stim-
ulated overnight with 1 ng/mL recombinant human IL-15. Pep-
tide pulsed 721.174 targets were prepared as for the stabilization
assays. Target cells were resuspended with PBMCs at an effector-
to-target (E:T) ratio of 5:1 in fresh R10medium containing peptide
and anti-CD107a-Alexa-fluor-647 antibody (eBioscience, Hatfield,
UK). Cells were incubated for 1 h at 26°C, then 6 μg/mL Golgi-
StopTM (BD Biosciences) was added, and incubated for a further
3 h at 26°C. Cells were washed in wash buffer (1% BSA/0.1%
NaN3) and blocked with blocking buffer (10% human serum in
PBS) for 30 min and then stained with the following antibodies:
anti-CD3-PerCP (Biolegend, San Diego, USA), anti-human CD56-
PE, and anti-human CD158b-FITC (both BD Biosciences). Cells
were fixed in 1% PFA and analyzed by flow cytometry. Individual
assays for each donor were performed once in duplicate and the
mean value used for subsequent analysis.
KIR and HLA genotyping
All donors were typed for KIR using a quantitative PCR compara-
tive Ct method [32]. Donors were typed for HLA-B and HLA-C at
the Anthony Nolan Institute (London, UK) using Luminex xMAP R©
technology.
Statistics
These were calculated using GraphPad Prism by two-way ANOVA
to compare KIR2DL2 and KIR2DL3 homozygous donors, with
a post Student’s t-test and Bonferroni correction to compare
individual data points.
Data modeling
We constructed a regression model using the experimental data.
The model assumes that the degranulation (A), quantified by
CD107a in a population of NK cells, varies with concentrations
of FA, DA, and RA peptides as:
A = 100% − kF [FA] − kD [DA] − kR [RA] + kDF [DA] [FA]
+ kFR [FA] [RA] + kRD [RA] [DA] + kDFR [DA] [FA] [RA] (1)
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In the above expression, [x] denotes the concentration of a
peptide, x; kF, kD, kR, kDF, kFR, kRD, and kDFR are model parame-
ters that are evaluated by fitting the above expression to the data
characterizing NK cell activation stimulated by mixtures of the
three peptides. The terms linear in the concentrations in Eq. (1)
describe inhibition of NK cell activation when NK cells are stimu-
lated individually by the peptides. The terms proportional to the
product of two peptide concentrations describe the antagonistic
effect induced by the peptides. The last term describes the effect of
a triple peptide stimulation that cannot be captured by pair-wise
stimulations of the peptides. NK cell activation is assumed to be
100% in the absence of any DA, FA or RA peptide. We determine
the parameters in Eq. (1) by fitting the expression with the data
from the three-peptide mixture experiments. Then we use Eq. (1)
to address two principal issues:
(1) To quantify differences between the data generated from
the KIR2DL2 and the KIR2DL3 donors in terms of the parameter
values.
(2) To quantify differences between the ability of the NK cells
from the KIR2DL2 and the KIR2DL3 donors to respond when the
peptide mixtures stimulate the cells.
We calculated the parameters in Eq. (1) by minimizing χ2 as
defined below. χ2 quantifies the difference between the model
and the experimental data.
χ2 =
∑
i
(
Aexpti − Amodeli
σ
expt
i
)2
(3)
where, i refers to an experiment with any mixture of the three
peptides, FA, DA, and RA. Aiexpt denotes the average value of
the % of CD107a degranulation measured over multiple trials
(n > 3) for a particular mixture of peptides indexed by i. σiexpt
denotes the variance in the measured % of CD107a degranulation
in the trials done in the ith experiment. In the experiments, the
peptide combinations were chosen such that the total concentra-
tion of the peptides was held fixed at 10μM, i.e. [FA]+[DA]+[RA]
= 10 μM. Aimodel represents the % of CD107 degranulation calcu-
lated from Eq. (1) for the peptide concentrations corresponding to
the ith experiment. We chose the parameters that minimized χ2 in
Eq. (3). Theminimization was carried out by the routine lsqcurvefit
in MATLAB.
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